Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

*Amsterdam UMC, location VUMC, Vrije Universiteit Amsterdam, Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands; and

†Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology.

Correspondence: H. J. Bogaard, MD, PhD, Professor of Experimental Pulmonary Medicine, Pulmonologist, Department of Pulmonary Medicine, Amsterdam University Medical Center, Location VUmc, De Boelelaan 1117, Room number 5A-072 1081 HV Amsterdam, The Netherlands (e-mail: [email protected]).

Supported by an unrestricted grant from the Amsterdam Medical Center Foundation and a Bottom-up Grant from NWO ZonMW (Grant number 10430 01 201 0007). In addition, this project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant agreement No. 101005142. The funding sources had no role in the design of the study, data collection and analysis, or decision to submit the paper for publication.

J. Aman and A. Vonk Noordegraaf are inventors of a patent (WO2012150857A1, 2011) covering protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase Abl-related gene (Arg). The remaining authors report no conflicts of interest.

Data sharing: Qualified researchers can request access to anonymized patient-level data and related study documents after publication. Study documents include the study protocol, structure of the electronic case report form, statistical analysis plan, and data set specifications.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jcvp.org).

A. Vanhove, E. Duijvelaar, J. R. Schippers, and P. J. Smeele acquired the data and take responsibility for the integrity of the data. E. Duijvelaar performed the statistical analyses. A. Vanhove, E. Duijvelaar, F. S. de Man, H. J. Bogaard, J. Aman, J. R. Schippers, P. J. Smeele, and Y. Pinto were involved in data interpretation and drafting of the manuscript. All authors provided critical feedback on the manuscript and approved the final version. All authors had full access to the study data and take responsibility for the decision to submit the manuscript for publication.

E. Duijvelaar shared first authorship.

Clinical Trial Registration Information: This study was registered with the EU Clinical Trials Register (EudraCT 2020–001236–10, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001236-10/NL) and Netherlands Trial Register (NL8491, https://www.trialregister.nl/trial/8491).

留言 (0)

沒有登入
gif